Clinical program
We are committed to improving health for patients around the world and improving patient empowerment and increasing their confidence in our products and technology. It is our absolute commitment to ensure we supply safe products to patients, customers, and healthcare professionals. As our DSM portfolio grows, we are committed to investing in performing clinical studies and post-market clinical studies in order to generate more data about our products.
Our current clinical program includes the following studies.
| Acronym | Product | Protocol | Design |
|---|---|---|---|
| SirTac | EmboCept® S/ PlatiCept® | DSM-TACE + Cisplatin vs. SIRT (SIR speres, 90Y) for liver metastases in advanced uveal melanoma | Phase II, randomizedmulticentric |
| FASL | EmboCept® S DSM 50 µm | Lung tumors vs. transarterial chemoperfusion | Prospective randomized monocentric comparative study |
| HEPASTAR | EmboCept® S | Hepatocellular carcinoma management with transarterial chemoembolization with degradable starch microspheres (DSM-TACE) | Observational study |
